ASNC has confirmed reports that supply disruptions with both Tc-99m pyrophosphate (PYP) and Tc-99m hydroxymethylene diphosphonate (HMDP or HDP) may take place after January 2026. These products are used in the diagnosis of cardiac amyloidosis.
ASNC is in contact with the manufacturers of both products to understand the extent of the shortages and the projected timelines for resuming production.
ASNC will share updates as this issue evolves. To be among the first to receive email alerts with breaking news, be sure to keep your ASNC membership current.
Article Type
News & Announcements
Category
Advocacy
Related Posts
Immediate Impact! ASNC Statement Driving Cardiac PET Adoption Across the United States
“ASNC’s Clinical Indications for PET statement got the attention of our hospital…
This Legislation Would Halt Pay Cut Now Impacting Most Physician Services
“The 2.5% reduction to work RVUs – the so-called ‘efficiency adjustment’ –…
Manufacturer Shares Update on HMDP Supply
ASNC is staying in touch with radiopharmaceuticals manufacturers that were expecting shortages…

